Erectile dysfunction at 40 and at 60 typically reflect different underlying problems. At 40, new ED is often a cardiovascular warning sign, a medication side effect (particularly SSRIs), or psychogenic. At 60, it's usually vascular — established hypertension, diabetes, or atherosclerosis showing up in the penile arteries. The first-line treatment is the same (PDE5 inhibitors), but the workup priorities differ, and the urgency of evaluating underlying disease differs too.
ED prevalence rises steeply with age: about 5% of 40-year-olds, 15–25% of 50-year-olds, 40% of 60-year-olds, and 50%+ of 70-year-olds report clinically significant ED. What this means practically: ED at 40 is unusual enough to warrant a broader workup for underlying drivers; ED at 60 is common enough that most cases are driven by age-standard vascular or metabolic factors, though a new-onset case still deserves cardiovascular screening.
New ED in a man in his 40s is clinically different from new ED in a man in his 60s. It's a statistical outlier in its age group, which makes it a more specific pointer toward something identifiable and often addressable.
The emphasis is on screening for reversible and cardiovascularly-important drivers. A PDE5 inhibitor treats the symptom, but missing the underlying driver at 40 can mean missing a cardiac risk window or failing to swap an SSRI for a sexually-neutral alternative (bupropion is the classic swap).
By 60, age-related changes in blood vessel function, hormone levels, and often accumulated chronic disease (diabetes, hypertension, atherosclerosis) make ED common. It's still worth treating — effectively — and still worth ensuring the workup has covered the bases.
At 60, the main priorities are: confirming cardiovascular status is well-controlled before starting a PDE5, reviewing current medications for ED-worsening drugs, checking glucose control if diabetic, and considering BPH if urinary symptoms coexist. A one-pill-for-two-conditions approach with daily tadalafil works well here.
| ED at 40 | ED at 60 | |
|---|---|---|
| Prevalence | ~5% of men | ~40% of men |
| Most likely driver | Cardiovascular warning, SSRI, psychogenic | Established vascular disease, diabetes, BPH |
| Urgency of cardiovascular workup | High — may precede a cardiac event by years | Usually already underway or completed |
| Medication review importance | Very high (especially SSRIs) | Very high (longer med list) |
| Starting PDE5 dose | Standard (sildenafil 50 mg, tadalafil 10 mg) | Often start lower and titrate (25 mg sildenafil, 5 mg tadalafil) |
| First-line pattern | On-demand typical | On-demand or daily tadalafil (if BPH coexists) |
| Response rate | Excellent (>70%) | Good (>60%; diabetes lowers it somewhat) |
Typical starting point: sildenafil 50 mg on-demand or tadalafil 10 mg on-demand, paired with a conversation about blood pressure, sleep, weight, and any SSRI or other contributing medication. If a medication swap can address the ED without adding a drug, that's often the cleaner path (SSRI → bupropion, or beta-blocker → non-ED-aggravating alternative after cardiology input).
Typical starting point: sildenafil 25–50 mg or tadalafil 5–10 mg, with attention to drug interactions (many men at 60 take 5+ medications). If BPH symptoms coexist, daily tadalafil 5 mg is a strong choice — one pill, two conditions treated. If diabetes is present, glucose control and glycated hemoglobin optimization improves ED response alongside PDE5 medication.
PDE5 inhibitors are contraindicated with nitrates (nitroglycerin, isosorbide, recreational "poppers") at any age. They're relatively contraindicated with recent MI (within 6 months), severe heart failure (NYHA class III–IV), unstable angina, or uncontrolled hypertension. These rule-outs matter more at 60 than 40 simply because the base rate of each is higher.